Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Asia-Pacific growth outlook lifted to 5% for 2026

    September 24, 2026

    13th Silk Road International Film Festival Concludes in Xi’an with Golden Silk Road Awards Announced

    September 24, 2026

    UAE joins Trump meeting on Middle East security in New York

    September 23, 2026
    Aljazair TimesAljazair Times
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Aljazair TimesAljazair Times
    Home » Yuyu Pharma to attend ‘CPHI Worldwide 2023’
    PR Newswire

    Yuyu Pharma to attend ‘CPHI Worldwide 2023’

    October 18, 2023
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    SEOUL, South Korea, Oct. 18, 2023 /PRNewswire/ — Yuyu Pharma will be attending CPHI Worldwide in Barcelona, Spain from October 24th to October 26th.

    Yuyu Pharma to attend ‘CPHI Worldwide 2023’

    The Yuyu Business Development team will be able to meet great partners at booth #7G30 in the Korean Trade Association pavilion to introduce Yuyu’s export products such as its modified new drug Maxmarvil EC Tablet, Yuhylyx soft capsules, Yuvaro, and Senuvela Tab, among others.

    In particular, Yuyu will focus on promoting projects currently under development, such as a reduced sized Dutasteride and Dutasteride-Tamsulosin combination drug. These projects are being developed with the goal of entering the U.S. and European Benign Prostate Hyperplasia

    Danny Kang, Export Manager at Yuyu said “As always, we look forward to having active discussions with partners at our CPHI booth. And hope to meet new potential partners as well”

    About Yuyu Pharma

    With over 80 years in the healthcare industry, Yuyu Pharma (KRX: 000220) is a rapidly scaling global pharmaceutical company founded in Seoul, South Korea. Yuyu is committed to developing innovative therapeutics in the areas of neurology, dermatology, urology, and ophthalmology. Yuyu’s Mission is to improve the quality of life and enhance well-being for all individuals by developing innovative healthcare products and services.

    Photo – https://mma.prnewswire.com/media/2249315/1.jpg

    Cision View original content:https://www.prnewswire.co.uk/news-releases/yuyu-pharma-to-attend-cphi-worldwide-2023-301959839.html

    Related Posts

    13th Silk Road International Film Festival Concludes in Xi’an with Golden Silk Road Awards Announced

    September 24, 2026

    Co-Creating Future Transit Value: CRRC Brings Three Full-Size Trains and End-to-End Solutions to InnoTrans 2026

    September 23, 2026

    China Daily: Chinese farming model offers practical lessons for Global South

    September 21, 2026

    Binance Launches Foreign Exchange Perpetual Futures, Expanding 24/7 Access to the Largest Financial Market

    September 18, 2026

    Skye Africa Intelligence Commissioned to Develop SafariOS Hospitality Concierge in Tanzania

    September 18, 2026

    Jiahui Health Highlights China’s Growing Role in Global Medical Tourism at WTO Public Forum 2026

    September 18, 2026
    Editor's Pick

    Asia-Pacific growth outlook lifted to 5% for 2026

    September 24, 2026

    UAE joins Trump meeting on Middle East security in New York

    September 23, 2026

    Egypt overseas transfers total $29.7 billion through July

    September 22, 2026

    Typhoon Dujuan brings flood risk and travel disruption

    September 21, 2026

    China keeps loan prime rates steady through September 2026

    September 21, 2026

    Rare EGFR mutation raises lung cancer risk 60 times in data

    September 19, 2026

    Nepal flood missing count rises to 6,150 after verification

    September 17, 2026

    WHO reports Ebola progress as DR Congo outbreak continues

    September 17, 2026
    © 2026 Aljazair Times | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.